Bemitil in lupus, Thymodepressin in psoriasis and arthritis, and the wider immune-peptide literature—organized by what the sources actually measured.
The central question is whether pathological immune activity can be influenced while protecting injured tissues and cellular energy systems. Immune suppression, restored tolerance and tissue protection are different goals. An improvement in fatigue or motor function does not by itself demonstrate control of autoimmunity.
This is an educational research map. These investigational findings do not establish a replacement for disease-modifying care.
IMMUNE SUPPRESSION
Reduce pathological activity
Thymodepressin’s pharmacology and the lupus antibody signal are relevant leads. Broad suppression is not selective removal of autoreactive cells.
IMMUNE TOLERANCE
Restore recognition of self
Antigen-directed formulations such as Xemys explore a different strategy. Cytokine shifts alone cannot prove durable, selective tolerance.
TISSUE PROTECTION
Limit injury and dysfunction
Bemitil and Cortexin raise functional and metabolic questions. Tissue protection must be evaluated separately from relapse, organ damage and disability progression.
Small comparisons, patent cases and Phase I program
No established disease-modifying benefit
Lupus: Bemitil’s human antibody signal
A 1999 Russian study followed 61 patients in four groups over eight weeks. It reported lower anti-DNA antibodies and improved SLEDAI-1/ECLAM activity measures in Bemitil-containing groups. The related patent clarifies that these groups also received glucocorticoids, with or without cyclophosphamide. This was adjunctive treatment. The paper and patent describe the same research program, not two independent confirmations. Allocation, disease-severity differences and concurrent treatment prevent a confident causal conclusion.
1999 · The effect of bemetil on production of DNA antibodies in patients with systemic lupus erythematosus
Format: Indexed English abstract · Reviewed: Abstract reviewed
T. A. Lisitsyna, A. D. Durnev, M. M. Ivanova, A. I. Speranskii, S. B. Seredenin, V. A. Nasonova · Experimental and Clinical Pharmacology. 1999;62(5):38–41. PMID 10572751
A four-group lupus report associated Bemitil-containing treatment with lower anti-DNA antibody levels and disease-activity scores; the abstract does not give numerical changes.
Findings, study figures and available tables
Reported findings and study design
A four-group lupus report associated Bemitil-containing treatment with lower anti-DNA antibody levels and disease-activity scores; the abstract does not give numerical changes.
Four groups of 15, 15, 15 and 16 patients; background prednisolone with different adjuncts; eight-week assessment.
Dose, route and schedule
Bemitil: 500–750 mg/day orally for eight weeks, studied alone or with cyclophosphamide. Combination-arm results do not establish Bemitil’s independent effect.
Reported findings and study figures · Primary-publication indexed abstract; no full-text table appraisal
Measure
Result
Comparison, timing and statistics
Antibodies and lupus activity
Reported decreases in anti-DNA antibodies, SLEDAI-1 and ECLAM scores
No group-level values or effect sizes in abstract
Group sizes
15, 15, 15 and 16 patients
Do not treat all as one Bemitil arm
Bemitil exposure
500–750 mg/day orally
Eight-week comparison; the indexed background-drug dose units need original verification
Several concurrent-treatment arms prevent interpreting this as Bemitil monotherapy. Unverified background-drug units are not reproduced as dosing instructions.
Format: Russian patent with English translation · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
T. A. Lisitsyna and colleagues · RU2157684C2. Filed 22 December 1997; published 20 October 2000
The patent describes four treatment groups using glucocorticoids with or without cyclophosphamide and Bemitil. It reports improvements in selected clinical and laboratory signs and anti-DNA antibodies in the Bemitil groups. This appears to describe the same research program as the 1999 paper.
Findings, study figures and available tables
Reported patent results
Reported findings
The patent reports lower anti-DNA antibodies and steroid changes in adjunctive Bemitil arms of the historical lupus program; unequal groups and follow-up prevent a causal efficacy estimate.
Same 61-patient lupus program as the 1999 publication; all Bemitil arms also received glucocorticoids.
Reported findings and study figures · Source passages checked 5 November 2026; see study record for access and limitations.
Measure
Result
Comparison, timing and statistics
Anti-DNA antibodies
Reported within-group reductions in both Bemitil-containing arms
p<0.001
Mean daily prednisolone, group 3
23.5 → 18.7 mg/day during observation
Mean daily prednisolone, group 1
14.7 → 29.0 mg/day during observation
Reported relapses / exacerbations
11/30 without Bemitil at 6–12 months; 5/31 with Bemitil at 12–18 months
Historical treatment observations, not dosing advice. Unequal follow-up, baseline severity and treatment selection preclude a causal steroid-sparing claim or comparative relapse-risk calculation. Patent and paper are not independent replication.
The 140-patient 2014 report contains a large PASI signal, but its often-quoted 90% versus 41% comparison appears in the discussion of moderate psoriasis, not an explicitly verified denominator of all 140 participants. The earlier 50-completer report includes seven treatment withdrawals for skin eruptions. A separate 72-patient study compared combination treatment against peptide monotherapy; both groups received Thymodepressin. In 2017, 48 patients entered three randomized groups, while five pregnant patients formed a separate cohort. These studies need independent replication with clear allocation, denominators and longer safety follow-up.
2014 · Evaluation of the efficacy and safety of a Russian selective immune suppressor in treating patients with psoriasis
2014Human comparative studyRussian source · see review scope
A. A. Kubylinskiy, N. G. Korotkiy, A. A. Tikhomirov, V. Yu. Udzhukhu, N. M. Sharova · Clinical Dermatology and Venereology. 2014;12(5):68–74
The Russian text reports more than 75% PASI improvement by day 25 in 90% versus 41% in the moderate-disease comparison. Overall favorable outcomes were reported in 100% versus 82.9%.
Findings, study figures and available tables
Reported findings and study design
140-patient clinical comparison; the quoted PASI response appears within the moderate-psoriasis discussion.
Reported findings and study figures · Source passages checked 5 November 2026; see study record for access and limitations.
Measure
Result
Comparison, timing and statistics
PASI reduction greater than 75% by day 25
90% with Thymodepressin versus 41% with conventional care
The subgroup denominator is not verified; these percentages must not be described as responses among all 140 participants. Blinding, allocation and concurrent treatment limit attribution.
E. A. Batkaev, I. A. Chistyakova · Effective Pharmacotherapy. 8/2013
The authors report a 90.4% PASI reduction by day 20 and three-year remission in 70%. The same article describes seven withdrawals following drug-related skin eruptions.
Findings, study figures and available tables
Reported findings and study design
Historical clinical report with 50 course completers and seven reported discontinuations.
Reported findings and study figures · Source passages checked 5 November 2026; see study record for access and limitations.
Measure
Result
Comparison, timing and statistics
PASI change
Reported 90.4% reduction by day 20
Three-year remission
Reported in 70%; follow-up denominator and ascertainment need clarification
Treatment withdrawals
Seven cases after skin eruptions; no adverse-event rate inferred
Completer-only tolerability cannot represent everyone exposed. Historical comparisons and co-treatment prevent a reliable comparative efficacy estimate.
O. V. Degtyarev, V. V. Dumchenko, T. A. Tkachenko, O. V. Zhizhimova, E. G. Bakhmutova, I. N. Selivanova, I. A. Erina · Russian Journal of Skin and Venereal Diseases. 2014
The publication compares combination treatment against Thymodepressin monotherapy and reports categorical skin responses.
Population / setting
72 patients: 42 prednisolone plus Thymodepressin; 30 Thymodepressin alone
What was checked
Original publisher article and Russian/English summary checked.
Limitations & review scope
No group received neither treatment, so the independent effect of Thymodepressin cannot be estimated.
Some response percentages in the English abstract do not match their stated counts; no pooled response estimate is reproduced.
Source checked 2026-11-05. See the review scope above for the material assessed.
Read the source ↗2017 · Clinical evaluation of combined immunosuppressive therapy for psoriasis
2017Randomized trialRussian source · see review scope
Rheumatoid arthritis: a trial plan awaiting results
Protocol ИБХ-ТД01, registration No. 77 dated 4 February 2013, describes a Phase IV randomized, double-blind, placebo-controlled trial of Thymodepressin added to methotrexate. The record lists 142 planned participants, 14 sites and ACR20 at 12 weeks. ACR20 is a standardized threshold for clinical improvement. The accessed source is a third-party registry reproduction with study dates in 2013–2016. Actual recruitment, completion and outcome results remain unverified; the registration cannot demonstrate efficacy.
2013 · Thymodepressin plus methotrexate in rheumatoid arthritis — protocol ИБХ-ТД01
2013Trial protocol / registrationRussian source · see review scope
Pharma Bio — listed sponsor · Registration No. 77, 4 February 2013; protocol ИБХ-ТД01
Registry reproduction describes a Phase IV randomized, multicenter, double-blind, placebo-controlled add-on trial with ACR20 as the primary assessment. Listed dates: 4 February 2013 to 30 September 2016.
Inflammatory myopathies: a small dissertation comparison
Tatyana Alekseeva’s 2008 St. Petersburg doctoral abstract describes 15 patients receiving adjunctive Thymodepressin and 15 symptomatic-care comparators. Reported changes included proximal muscle strength, IL-8 and TNF-α. The IL-10 result was a nonsignificant trend. This is a research lead from a third-party transcription of the author abstract; an authenticated full thesis and independent controlled replication remain missing.
Tatyana M. Alekseeva · Doctoral dissertation author abstract. St. Petersburg, 2008
The author reports increased proximal arm and leg strength and lower IL-8 and TNF-α production; the IL-10 change was a nonsignificant trend.
Findings, study figures and available tables
Reported findings and study design
15 adjunctively treated patients versus 15 symptomatic-care comparators, reported in an author-abstract transcription.
Reported findings and study figures · Source passages checked 5 November 2026; see study record for access and limitations.
Measure
Result
Comparison, timing and statistics
Proximal arm strength
Reported increase
p<0.01
Proximal leg strength
Reported increase
p<0.001
IL-8 / TNF-α production
Reported reductions
p<0.01 / p<0.001
IL-10 production
Nonsignificant upward trend
p=0.08
These are reported pre/post signals, not verified between-group effect estimates. Original full-thesis authentication, allocation and durable outcomes remain unresolved.
Thymodepressin has a 22-patient autoimmune-cytopenia report. Thymalin, a different thymus-derived mixture, appears in a 25-patient cytopenia study with glucocorticoids and a thyroiditis study involving 104 patients. In the latter, 22 received plasmapheresis alone and 82 received additional Thymalin; 49 hypothyroid patients also received hormone replacement. That overlapping subset must not be counted as a third independent group. These multimodal treatments do not isolate a peptide’s contribution.
2002 · [Use of thymodepressin for treating autoimmune cytopenia]
2002Human study · design details unresolvedEnglish abstract
Vinogradova IuE, Zamulaeva IA, Pavlov VV, Selivanova EI, Deĭgin VI, Smirnova SG, Orlova NV, Saenko AS · Terapevticheskii arkhiv
The report describes higher hemoglobin in autoimmune hemolytic anemia and higher platelet counts in immune thrombocytopenia, alongside reductions in lymphocyte activation measures.
Population / setting
22 patients with autoimmune cytopenias
What was checked
Original publication abstract checked; full methodological appraisal pending.
Limitations & review scope
Uncontrolled clinical report; changes cannot establish an independent treatment effect.
The abstract supplies no reliable comparative effect size or comprehensive safety estimate.
Source checked 2026-11-05. See the review scope above for the material assessed.
Read the source ↗1991 · [The effect of immunocorrective therapy on immunity in patients with idiopathic autoimmune cytopenias]
1991Human study · design details unresolvedEnglish abstract
Thymalin and glucocorticoids were investigated in an immunocorrective treatment program; the abstract reports changes in immune measures.
Population / setting
25 patients with idiopathic autoimmune cytopenias
What was checked
Original publication abstract checked; full methodological appraisal pending.
Limitations & review scope
Concurrent glucocorticoids prevent attributing changes to Thymalin.
Allocation, clinical response definitions and long-term safety require the original paper.
Source checked 2026-11-05. See the review scope above for the material assessed.
Read the source ↗1994 · [Effect of plasmapheresis and immunocorrective therapy on the status of the T-cell component of immunity in patients with autoimmune thyroiditis]
Multiple sclerosis: function, biomarkers and antigen-directed research
Cortexin’s small clinical comparisons concern function and symptoms; Bemitil’s ten-case patent describes combined treatment. Neither establishes remyelination or relapse prevention. Xemys, a Russian-developed liposomal myelin-peptide formulation, adds a different research direction: antigen-directed immune modulation. Its 20-patient open-label Phase I report found unchanged EDSS and MRI measures at study exit, with a transient increase in active lesions at weeks 7 and 10. The related cytokine publication is from the same program, not an independent efficacy trial.
2009 · Effect of Cortexin on neuroplasticity in multiple sclerosis
Format: Publisher article and Russian PDF · Reviewed: Publisher full-text results narrative and available tables checked on 1 November 2026
S. V. Kotov, T. I. Yakushina, V. Yu. Lizhdvoy · Effective Pharmacotherapy. Neurology and Psychiatry. 2009;(3):14–16
Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.
Findings, study figures and available tables
Reported findings and study design
Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.
20 adults with relapsing-remitting MS in stable remission; two ten-day courses of 10 mg intramuscular Cortexin with a two-week interval; no control group.
Reported findings and study figures · Publisher full-text results narrative and available tables checked on 1 November 2026
Measure
Result
Comparison, timing and statistics
Beck depression score
17.6 ± 1.3 → 12.9 ± 1.4 points
Within-person change; 12 participants had depressive symptoms at baseline · After the treatment program · p<0.05 versus baseline
EQ-5D health score
0.41 ± 0.07 → 0.73 ± 0.03
Within-person change; higher score indicates better reported health · After treatment · p<0.05 versus baseline
EDSS disability
No significant change
Participants entered in remission with EDSS below 3
Adverse events
None observed in 20 participants
Small, short open study; not a long-term safety estimate
These results concern symptoms and quality of life in an uncontrolled cohort. Stable EDSS during a short remission-period study does not demonstrate remyelination or prevention of disease progression.
Format: Open-access journal PDF; Zenodo repository · Reviewed: Full article read; motor table visually checked
M. A. Artykova, S. A. Beknazarov · Scientific and Innovative Therapy. 2025;(2):3–9. Bukhara State Medical Institute; Zenodo deposit 5 June 2025
After three courses, the authors report upper-limb motor-score gains of 1.4 versus 0.8 points and lower-limb gains of 1.8 versus 0.9, with reported p<0.05. The proportion described as having reduced work capacity fell from 71.7% to 31.1% with adjunct Cortexin, versus 75.5% to 53.1% in controls. These are reported functional signals, not evidence of disease modification.
Findings, study figures and available tables
Reported findings and study design
63 adults with MS aged 18–59: standard care plus Cortexin 33 versus standard care 30; results reported after three courses.
Reported findings and study figures · Previously reviewed full-article motor table and reported work-capacity percentages
Measure
Result
Comparison, timing and statistics
Upper-limb motor-score gain
1.4 versus 0.8 points
p<0.05 as reported
Lower-limb motor-score gain
1.8 versus 0.9 points
p<0.05 as reported
Reduced-work-capacity proportion, add-on arm
71.7% → 31.1%
Reduced-work-capacity proportion, comparison arm
75.5% → 53.1%
Existing full-article extraction; the motor scale and variance are not adequately specified, and percentages lack raw counts. No MRI, relapse or EDSS progression benefit is established.
63 adults with MS, ages 18–59: 33 standard therapy plus Cortexin; 30 standard therapy alone
What was checked
Methods, results, tables and references reviewed. Randomization, blinding and allocation procedures are not described; this is not classified as a randomized trial.
Limitations & review scope
Small comparison with unclear allocation, baseline comparability, concomitant therapy and assessment timing; no placebo or blinding described.
Motor scale, variance and statistical methods are insufficiently specified. Percentages lack underlying counts; immune-marker claims have no numerical table.
No longitudinal MRI lesion, relapse-rate or EDSS progression outcomes are reported. Safety reporting is insufficient; this does not establish an MS treatment or replacement for disease-modifying therapy.
A same-title 2021 Artykova–Rakhmatov report exists; cohort overlap remains unresolved and is not counted as independent replication.
Source checked 2026-10-03. See the review scope above for the material assessed.
Read the source ↗2006 · Pharmaceutical composition and method for treating chronic fatigue syndrome due to its application
2006Patent / reported experimentsFull text available
Format: Patent full text · Reviewed: Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
O. V. Dorozhko, G. I. Kovalev, R. M. Salimov · RU2267319C2. Filed 15 July 2003; application published 10 February 2005; granted 10 January 2006
Example 5 describes a 47-year-old woman with MS receiving Bemitil alongside piracetam, pentoxifylline, B vitamins and massage. The patent reports improvements in strength, coordination, cognition, mood and sleep. It supplies neither a controlled MS trial nor complete results for all ten MS cases.
Findings, study figures and available tables
Reported patent results
Reported findings
The clinical examples describe improvement during adjunctive Bemitil treatment, without group-level efficacy scores or a controlled patient comparison.
Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
Reported findings and study figures · Description: Examples 3, 5 and 6; Table 3 and separate clinical group narratives.
Measure
Result
Comparison, timing and statistics
MS illustrative case
Reported clinical/MRI remission, improved strength, coordination, memory, mood and sleep
One 47-year-old patient also receiving piracetam, pentoxifylline and vitamins · After approximately 3 weeks
Chronic-fatigue illustrative case
Reported improvement in general condition, tremor, headaches, coordination and perceived weakness
One 29-year-old patient receiving several other medicines · After a 15-day course
Animal maze experiment
216.6 ± 12.1 s with Bemitil versus 304.9 ± 33.3 s after injury alone; uninjured control 224.3 ± 14 s
25 mice per group; duration to exploration criterion, not a patient disability score
No aggregate MS relapse, disability-progression or MRI-lesion outcome is supplied for the 10-patient group. Selected adjunctive cases cannot establish disease modification or ME/CFS efficacy.
Patent report of 10 patients with MS and a separate 10-patient chronic-fatigue group, plus animal experiments; concurrent medicines were used.
What was checked
Source text reviewed at the access level stated; no independent verification of patient data.
Limitations & review scope
Patent assertions, not a peer-reviewed efficacy trial; multiple simultaneous interventions prevent attribution.
The described baseline brain MRI had no pathological changes, making a claim of MRI remission uninterpretable.
Animal MPTP, glutamate and haloperidol experiments are not experimental autoimmune demyelination models.
Source checked 2026-11-06. See the review scope above for the material assessed.
Read the source ↗2016 · CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study
2016Human study · design details unresolvedFull text available
A. Belogurov Jr., K. Zakharov, Y. Lomakin, K. Surkov, S. Avtushenko, P. Kruglyakov, I. Smirnov, G. Makshakov, C. Lockshin, G. Gregoriadis, D. Genkin, A. Gabibov, E. Evdoshenko · Neurotherapeutics. 2016;13:895–904
EDSS and MRI measures were statistically unchanged at study exit. Active gadolinium-enhancing lesions increased transiently at weeks 7 and 10.
Findings, study figures and available tables
Reported findings and study design
Uncontrolled Phase I study; 20 MS patients enrolled at four Russian centers.
Reported findings and study figures · Source passages checked 5 November 2026; see study record for access and limitations.
Measure
Result
Comparison, timing and statistics
EDSS and MRI at study exit
No statistically significant change versus baseline
Active gadolinium-enhancing lesions
Transient increase at weeks 7 and 10
Small open-label study cannot establish clinical efficacy, restored tolerance or long-term safety. Early MRI activity remains relevant despite unchanged exit measures.
20 MS patients enrolled at four Russian centers; open-label Phase I
What was checked
Primary publication checked for Phase I design and clinical/MRI outcomes.
Limitations & review scope
Uncontrolled safety and proof-of-concept study; not evidence of reduced relapses or disability progression.
Early MRI activity must be considered alongside the authors’ tolerability findings.
Source checked 2026-11-05. See the review scope above for the material assessed.
Read the source ↗2016 · Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients
2016Human study · design details unresolvedEnglish abstract
Y. Lomakin, A. Belogurov, I. Glagoleva, A. Stepanov, K. Zakharov, J. Okunola, I. Smirnov, D. Genkin, A. Gabibov · Mediators of Inflammation. 2016:2847232
The paper reports changes in circulating cytokines and chemokines after Xemys exposure.
Population / setting
Biomarker analysis from the same Phase I Xemys research program
What was checked
Original publisher summary checked; linked full text available.
Limitations & review scope
Same clinical program as the Phase I report; not an independent efficacy trial.
Biomarker changes do not demonstrate restored immune tolerance or clinical disease modification.
Source checked 2026-11-05. See the review scope above for the material assessed.
Two indexed Russian reports from 2006 and 2007 concern adjunctive Vilon in type 1 diabetes. They describe immune, coagulation and fibrinolysis markers, with differences by age and severity. Enrollment, allocation and possible cohort overlap remain unresolved. These reports do not establish beta-cell preservation, restored immune tolerance or replacement of insulin.
2007 · Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus
Synthetic peptide / defined-sequence research · Journal publication
Kuznik BI, Isakova NV, Kliuchereva NN, Maleeva NV, Pinelis IS · Advances in gerontology = Uspekhi gerontologii 20(2):106-115. PMID 18306698
Adjunctive Vilon in type 1 diabetes was associated with immune and coagulation-marker changes, including antithrombin III, protein C and fibrinolysis. No autoimmune disease-modifying effect is established.
Findings, study figures and available tables
Reported findings and study design
Reported findings and study figures · Primary indexed abstract, PMID 18306698.
Measure
Result
Comparison, timing and statistics
Immune and coagulation markers
Reported changes during adjunctive Vilon treatment; numerical effect sizes not supplied
Type 1 diabetes report, not proof of beta-cell preservation, restored tolerance or replacement of insulin. Possible overlap with the 2006 publication prevents pooling.
Type-1 diabetes patients receiving adjunctive care
What was checked
Europe PMC indexed citation and abstract checked. Full original paper not reviewed.
Limitations & review scope
Enrollment and allocation are not established by the abstract; do not infer an insulin-replacement treatment.
Full methods, adverse-event reporting and independent replication remain to be appraised.
Source checked 2026-11-05. See the review scope above for the material assessed.
Read the source ↗2006 · Effect of thymomimetic vilon on blood coagulation system and fibrinolisis in diabetes mellitus type 1 patients of different age
The abstract reports coagulation and fibrinolysis changes during adjunctive Vilon treatment in type 1 diabetes, with weaker responses in older patients with severe disease. These are surrogate outcomes.
Findings, study figures and available tables
Reported findings and study design
Reported findings and study figures · Primary indexed abstract, PMID 17152731.
Measure
Result
Comparison, timing and statistics
Coagulation / fibrinolysis
Reported improvement, with less pronounced effects in older, severely affected patients
Allocation, sample size and independent effect size are not established from the abstract. Biomarkers are not disease-modifying outcomes; cohort overlap remains unresolved.
Mechanistic findings: relevant, but not clinical outcomes
The 2021 Thymodepressin paper includes small mouse autoimmunity experiments with lower anti-fibrillarin antibody responses, including after disease induction. This does not establish human lupus efficacy or superiority to cyclosporine. Selank’s spleen gene-expression findings and Imunofan’s review of inflammatory mediators support hypotheses. Bromantane’s 2002 and 2004 human T-cell experiments reported activation and survival effects. That raises a context-dependent question in autoimmunity; it demonstrates neither clinical benefit nor clinical worsening.
Experimental anti-fibrillarin autoantibody responses were lower in selected Thymodepressin groups, including comparisons begun after autoimmunity developed.
Population / setting
Small mouse autoimmunity experiments, approximately five to eight animals per group
What was checked
Primary open-access paper checked for animal endpoints and group sizes; not a completed systematic appraisal.
Limitations & review scope
Small induced-animal model, not a human lupus trial.
Comparisons against cyclosporine do not establish clinical superiority or equivalent human exposures.
The article combines experimental results with historical clinical discussion; those evidence types must remain separate.
Source checked 2026-11-05. See the review scope above for the material assessed.
Read the source ↗2024 · The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
Activated human peripheral-blood T lymphocytes in culture
What was checked
Indexed citation and abstract checked through Europe PMC / PubMed. Original methods and risk of bias not fully appraised.
Limitations & review scope
Human-derived cells are not a clinical trial; culture concentrations do not establish therapeutic exposure or immune benefit.
Source checked 2026-09-29. See the review scope above for the material assessed.
Read the source ↗2004 · [The effect of ladasten on the activation-induced expression of Fas receptor on T-lymphocytes and their sensitivity to Fas-induced apoptosis].
In human peripheral-blood T cells, Ladasten increased selected activation-related responses and reduced Fas-induced apoptosis, while largely leaving activation-induced Fas expression unchanged.
Findings, study figures and available tables
Reported findings and study design
Human peripheral-blood T-cell cultures; Ladasten 0.1–10 microM.
Reported findings and study figures · Previously retrieved indexed abstract; numerical statements checked against the saved source text
Measure
Result
Comparison, timing and statistics
TCR-linked proliferation and ERK2
Comitogenic effect reported
Fas-induced apoptosis
Reduced
Numerical cell-fraction changes absent
Fas-receptor expression
Virtually unchanged
Human-derived cells are not a clinical immune-treatment study.
Thymogen and Thymodepressin have different stereochemistry and peptide linkages, with opposing reported immune effects. Bestim is another distinct molecule. A thymus extract’s findings cannot be assigned to an isolated component. The 2024 chiral-peptide review provides identity context; each profile links its own evidence.
Compound-specific research, not a list of autoimmune treatments
Vascular and cellular hypotheses; evidence from other settings cannot establish autoimmune efficacy.
Bromantane is a separate T-cell activation question. Trekrezan and B300 have stress-resilience hypotheses, without validated autoimmune efficacy or combination-specific immune benefit in this collection.
What would change the evidence?
Recover the rheumatoid arthritis trial’s regulatory record, completion data and prespecified ACR20 results.
Retrieve authenticated full texts for the myositis dissertation and historical Thymalin reports, including allocation and adverse-event data.
Replicate Bemitil’s lupus findings with comparable background treatment and disease-specific outcomes, including antibody, complement and organ-damage measures.
Reconcile psoriasis denominators, treatment withdrawals and durability under blinded comparisons.
For MS, prioritize relapse rates, MRI activity and disability progression over isolated cytokine or motor-score changes.
Test whether any effect represents selective tolerance, generalized suppression or tissue protection; these cannot be inferred from the same marker.
MCAS and ME/CFS remain separate research questions. Findings from lupus, psoriasis or MS cannot be transferred to either condition without diagnosis-specific evidence.
15 historical source records were added in this review. Existing lupus, Cortexin and Bromantane records are linked rather than duplicated. Sources include original Russian journals, international publications from Russian research programs, and explicitly labeled registry or dissertation reproductions.